News

Cramer Queries Lisa Su on AMD's Meta Equity Strategy

Cramer Queries Lisa Su on AMD's Meta Equity Strategy

When Cramer Takes Aim at AMD's Deal Structure

Flipping channels during a dull Tuesday, Jim Cramer had the nerve to lay down some hard truth as he grilled Lisa Su regarding Advanced Micro Devices (AMD) linking equity participation to their AI partnership with Meta Platforms (META). What’s the deal here? Meta gets performance-based warrants for 160 million shares—nearly a tenth of AMD. Cramer made a solid point: Nvidia scrapped any share-give-ups in their own partnership with Meta. Why is AMD playing ball differently?

AMD’s Strategic Gambit Under Cramer’s Microscope

Staring into the camera, Cramer pressed Su hard about the motives behind this choice. It’s not just a casual agreement; we're talking about a multiyear AI infrastructure deal here. The numbers are big: deploying 6 gigawatts of AI compute capacity — powered by AMD's Instinct GPUs — that could reshape AMD’s revenue stream. With performance-driven equity on the line, is AMD showing strength or weakness? Cramer seemed to suggest the latter.

"Why is Meta taking a share in you?" Cramer pressed, pointing out Nvidia's approach.

Su Stands Firm on the Partnerships

In Su’s defense, her response was as feisty as it was hopeful. She labeled the setup a transformative win for all parties involved. It’s a brave move, claiming that the AI accelerator market could shoot up to a staggering $1 trillion in just five years. Talk about ambition! She stressed that co-optimization and scale are necessities in this fast-paced market.

But let’s be real for a second: is that even possible without giving up equity? That’s the real takeaway from this whole conversation. Su argued every gigawatt represents billions in revenue. Yet, the undercurrent of skepticism still lingers—did AMD really need to play ball this way?

The Bigger Picture: AI’s Evolving Landscape

Meanwhile, AMD isn’t just fidgeting with Meta. They inked a massive deal with OpenAI that’s pegged to churn out about $135 billion. Yep, you heard me right! Six gigawatts of GPUs heading into OpenAI’s data center stylings, and guess what? There’s more equity on the line—another 160 million shares in play based on performance milestones tied to a hefty $600 share price. Suddenly, equity stakes aren’t looking so cozy, right?

"This structure ensures mutual upside," Su claimed, holding tightly to her optimistic narrative.

Market Reactions and Future Implications

You can’t ignore the swift market moves either—AMD surged 8.77% right after the Cramer interview. That speaks volumes, but there’s a catch: AMD still lags behind in the short-to-medium term outlook. Long-term price trends look bullish, but what good are those if the company is constantly giving away pieces of itself to stay relevant? Market sentiment measures can be deceiving, folks.

  • AMD's share price is volatile but trending upward.
  • Market skepticism about AMD's equity deals remains palpable.
  • Big swings in trading volume reflect investors' uncertainty.

Checking the scoreboard, Meta rose marginally during regular trading but floundered post-market. Those after-hours jitters tell you a thing or two: investors are on edge about commitments like these. Critical questions loom over AMD's trajectory. If future AI market growth is anyone's guess, this might just be the beginning.

Investors, Take Note

Here’s the sobering reality, traders: these equity warrants could define AMD’s future strategy, either lifting it to the heights of AI saturation or dragging it into the muddied waters of overpromised potential. The chip game is brutal, and while Cramer’s barbs get under Su's skin, they also illuminate the jittery dance between risk and reward in an industry packed with giants. Will AMD remain a cutthroat player or stumble under its own weight? Keep your eyes peeled—AMD's strategy in this flare of AI growth could be a game-changer or a wreck waiting to happen.

Every decision made these days has consequences, so tread carefully and stay informed. One thing's for sure: this story isn't over yet.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Agroz's Big Leap: New Supply Deal in Malaysia

Updated Category News Views 3

Agroz Inc. Executes a Game-Changing Deal If anyone thought the ag tech players were sitting idle, think again. Agroz Inc., noted for their innovative controlled-environment agriculture, just inked a pivotal deal with Harvest Hive in Malaysia. It's not just a nod to expansion—it's a strategic leap into the big leagues. Picture this: Harvest Hive's sprawling 500-acre farm...

Continue Reading
RARE Foundation Rebrands, Focus Still Strong

Updated Category News Views 3

Unveiling the RARE Foundation's New Identity In the stock market, you ride waves of change, and let me tell you, it ain't just stocks and bonds that change names and faces. Case in point: The EveryLife Foundation for Rare Diseases has spiffed up as the RARE Foundation. New name, new logo, the whole enchilada. This isn't just a cosmetic touch-up, though. It's about...

Continue Reading
Cove Capital Secures $9.96M for Debt-Free Logistics DST

Updated Category News Views 3

Unpacking Cove Capital's Latest Victory Cove Capital Investments has pulled off another coup, raising a hefty $9,964,510 for its Cove Essential Net Lease Industrial 108 DST. It's a Regulation D, Rule 506(c) offering, now fully subscribed, spotlighting a debt-free investment ethos and a rock-solid logistics site in Anchorage, Alaska. Strategic Facility Anchoring Investment...

Continue Reading
CUBEX Lights Up Veterinary Care with Mini Essential

Updated Category News Views 5

Inventory Woes? Meet Mini Essential If you’ve ever worked in or around veterinary hospitals, you know the old-school headaches of managing controlled substances. Picture this: piles of paper logs, end-of-shift recounting, and inevitable discrepancies that rear their ugly heads long after closing time. Enter CUBEX, shaking things up with their latest launch, Mini...

Continue Reading
MCatalysis Secures $5M to Disrupt Fuel Cost Dynamics

Updated Category News Views 3

Funding Fuels Innovation MCatalysis has just secured a hefty $5 million in seed funding to throw down with the big dogs in energy production. This isn't your regular backyard science project; this company is serious about changing the game with a tech-driven approach that could undercut current fuel prices. HL Energy Ventures and Oxford Science Enterprises are backing...

Continue Reading
Midlife ADHD in Women: New Challenges and Solutions

Updated Category News Views 5

ADHD Evolution in Women's Midlife They say change is the only constant, and boy, does that ring true for women navigating the turbulent seas of ADHD as they hit 40 and beyond. According to Germaine Swanson, the ADHD landscape changes dramatically in midlife, especially for women. We're talking about a mix of hormonal shifts, increasing life demands, and changes in brain...

Continue Reading
Tampa General’s Innovation Excellence Earns No. 20 Spot

Updated Category News Views 7

A Bold Leap into Innovation at Tampa General There's a heck of a lot going on down in Tampa that's worth more than just a golf clap. Tampa General Hospital (TGH) just snagged the 20th spot on Fast Company's Best Workplaces for Innovators list, and let me tell you, that’s no small feat amidst the heavy hitters in verticals like biotech and consumer goods. It takes guts...

Continue Reading
Give Lively & Change Simplify CA Nonprofit Compliance

Updated Category News Views 1

A Fresh Wind Blowing for California Nonprofits So, here's a twist in the nonprofit world that's stirring the pot just right. Give Lively and Change have partnered up to tackle the thorny issue of regulatory compliance in California. It's a big win for the nonprofits looking to keep fundraising through Give Lively without getting tangled in the bureaucratic web spun up by...

Continue Reading
Veho's Role in Redefining Beauty E-Commerce Delivery

Updated Category News Views 2

Veho Grabs Headlines with BeautyMatter Awards Nod Here's something a bit off the beaten path: Veho's been tapping into new wells of opportunity in the e-commerce sector, and their latest accolade demonstrates just that. Named a finalist in the 2026 BeautyMatter Awards under the Logistics category, they're making noise in all the right circles. Beyond Boxes: Transforming...

Continue Reading
RevSystems Joins Elite OpenAI Partner Network

Updated Category News Views 3

RevSystems Inks Deal with OpenAI Partner Network In the latest shuffle of the AI advisory deck, RevSystems just found itself elbowing into the exclusive OpenAI Partner Network. Based out of New York, RevSystems has carved a niche by spinning tech wizardry into tangible business results. Their new status as an OpenAI Select Partner puts them on a playing field where AI...

Continue Reading

Top 5 Most Recently Viewed Articles

Natural Diamonds Resilient Amid Market Shifts and Trends

Updated Category News Views 679

The Strength of Natural Diamonds in Today's Market As we enter a new year, the natural diamond market has shown a robust performance, providing encouraging signs of stability, strength, and growth. Jewelers have reported solid year-end results, showcasing steady or improved sales levels compared to previous periods. This positive trend reinforces the perception of natural...

Continue Reading
Bicara Therapeutics' Plans for Public Offering Showcase Growth

Updated Category News Views 183

Overview of Bicara Therapeutics' Initial Public Offering Bicara Therapeutics Inc. (NASDAQ: BCAX), an innovative biopharmaceutical company currently in the clinical stage, has just taken an exciting step forward. They've announced the pricing for their initial public offering (IPO), which includes 17,500,000 shares of common stock, each priced at a competitive $18.00. This...

Continue Reading
Class Action Alert for Semtech Corporation Investors

Updated Category News Views 107

Legal Update for Semtech Corporation Shareholders The Gross Law Firm has released an important notice specifically for shareholders of Semtech Corporation (NASDAQ: SMTC). This notice comes in light of a class action lawsuit that has been filed, and it outlines essential details regarding the lawsuit and actions that shareholders can take to safeguard their rights....

Continue Reading
Critical Insights on the Beyond Meat Securities Investigation

Updated Category News Views 241

Understanding the Investigation into Beyond Meat Beyond Meat, Inc. (NASDAQ: BYND), renowned for its innovative plant-based meat alternatives, is currently under scrutiny regarding potential violations of federal securities laws. This investigation, announced by a leading securities law firm, raises concerns for investors who may have suffered losses due to possible...

Continue Reading
Immunic Navigates Investor Events As Trials Advance

Updated Category News Views 2

Braving the Investor Circuit Immunic's ready to make some moves this July—this crew's diving headfirst into a trio of investor conferences. They're not just chitchatting; they’re taking one-on-one meetings, holding fireside chats. What’s the big draw? Their brainchild, vidofludimus calcium (IMU-838), which is knee-deep in phase 3 trials for relapsing multiple...

Continue Reading